Author: admin
Webinar Presented by Integral Molecular and Fierce Biotech – Best Practices for Antibody Specificity Testing for IND Submissions
Thursday, June 5, 2025 View the recording Off-target binding can be a significant hurdle in the development of antibody-based therapies, contributing to both drug […]
Integral Molecular Launches Paratope-PLUS™, a CDR-Scanning Service to Support Robust Patent Claims and Antibody Engineering
Technology aligns with new USPTO guidance for writing antibody patent claims and enables antibody engineering for novel intellectual property Philadelphia – Integral Molecular, a […]
Integral Molecular’s Out-licensed Bispecific Antibody Enters Clinical Trial for Treating Solid Tumors
Philadelphia –Integral Molecular, a leader in antibody discovery against membrane proteins, is pleased to announce that its out-licensed anti-Claudin 6 (CLDN6) bispecific antibody, CTIM-76, […]
FDA Accepts Integral Molecular’s Membrane Proteome Array™ Qualification Plan, Advancing the Platform for Approval as a Drug Development Tool
Philadelphia – Integral Molecular, a leader in antibody discovery technologies, is proud to announce that the FDA has accepted their Membrane Proteome Array™ (MPA) […]
Webinar Presented by Integral Molecular and The Antibody Society – How Specific are Antibody Drugs? Revealing insights from a new generation of specificity assays
Thursday, February 27, 2025 8 am PT, 10 am CT, 11 am ET View the recording Limitations of conventional specificity tools have contributed to […]
Integral Molecular Awarded $2.7 Million to Advance the Membrane Proteome Array™ Towards FDA-Qualification as a Drug Development Tool
Integral Molecular, a leader in antibody discovery and characterization, has been awarded $2.7 million by the NIH Commercialization Readiness Pilot (CRP) Program. This funding […]